Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
127.12
+3.51 (+2.84%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharma Plc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Q3 Proves To Be Another Tough Quarter For Cannabis
November 28, 2022
It’s been a tough year for cannabis investors and Q3 offered little relief.
Via
Talk Markets
Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling
November 28, 2022
The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Want to Double Your Money? Buying These Stocks Could be a Genius Move
November 28, 2022
These stocks are undervalued considering their long-term growth potential.
Via
The Motley Fool
Prediction: This Growth Stock Could Double in 2023
November 24, 2022
The next year should be a busy one for this drugmaker.
Via
The Motley Fool
Three CBD Stocks to Dominate a Budding Industry
November 23, 2022
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.
Via
MarketBeat
Topics
Cannabis
Exposures
Cannabis
Product Safety
Is Axsome Therapeutics Stock a Buy Now?
November 11, 2022
The company seems to be coming into its own.
Via
The Motley Fool
Why Shares of Zymeworks Rose 12.18% on Monday
October 31, 2022
The biotech stock's shares may have been pushed by a short squeeze.
Via
The Motley Fool
Why Zymeworks Stock Is Soaring Today
October 19, 2022
Investors applauded a major licensing deal with Jazz Pharmaceuticals.
Via
The Motley Fool
Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling
November 21, 2022
Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent.
Via
Benzinga
Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent
November 21, 2022
Via
Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
November 20, 2022
Innovative products and services could keep these companies growing.
Via
The Motley Fool
3 Top Cannabis Stocks to Buy in November
November 20, 2022
These solid performers are managing to grow revenue in a difficult environment.
Via
The Motley Fool
2 Dirt Cheap Growth Stocks to Buy and Hold for Years
November 18, 2022
In the long run, these stocks could deliver great returns.
Via
The Motley Fool
What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals
November 10, 2022
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:
Via
Benzinga
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
November 10, 2022
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.
Via
Benzinga
Why Axsome Therapeutics Stock Slipped Today
November 07, 2022
Investors traded out of the company following the latest earnings release, but only to a modest degree.
Via
The Motley Fool
3 Top Healthcare Stocks to Buy for November
November 04, 2022
Catalysts lie ahead for these promising stocks.
Via
The Motley Fool
2 Marijuana Stocks That Are Set for a Comeback
October 28, 2022
Don't overlook these top stocks when investing in the marijuana space.
Via
The Motley Fool
Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval
October 26, 2022
A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals...
Via
Benzinga
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
October 21, 2022
Via
Benzinga
Why Is Zymeworks (ZYME) Stock Up Today?
October 19, 2022
Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ).
Via
InvestorPlace
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
October 19, 2022
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
October 18, 2022
These two durable companies can navigate the market downturn and beyond.
Via
The Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
October 13, 2022
Investors are betting on these companies' revenue growth prospects.
Via
The Motley Fool
3 Top Marijuana Stocks to Buy for the Long Haul
October 07, 2022
The three have the financial strength to benefit from increased cannabis sales and cannabis therapies.
Via
The Motley Fool
3 Stocks Savvy Investors Are Buying Hand Over Fist
October 06, 2022
These high-flying stocks are defying the bear market.
Via
The Motley Fool
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit
September 29, 2022
A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision...
Via
Benzinga
UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar
September 29, 2022
Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading.
Via
Benzinga
5 Analysts Have This to Say About Jazz Pharmaceuticals
September 21, 2022
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.